News | Heart Failure | September 19, 2017

Heart Failure Market to Surpass $16 Billion by 2026

GlobalData report says growing uptake of Novartis’ Entresto will drive much of the anticipated growth

Heart Failure Market to Surpass $16 Billion by 2026

September 19, 2017 — The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is set to grow from $3.7 billion in 2016 to around $16.1 billion by 2026, according to research and consulting firm GlobalData. This represents an impressive compound annual growth rate of 15.7 percent.

The company’s latest report states that the strongest driver of this rise in market value will be the growing uptake of Novartis’ Entresto over the forecast period, despite initial modest sales. Other drivers will include the launch of several chronic heart failure therapies, including Amgen and Cytokinetics’ omecamtiv mecarbil, and an increase in the global prevalence of chronic heart failure and incidence of acute heart failure.

Elizabeth Hamson, Ph.D., healthcare analyst for GlobalData, explains: “Over the past two decades, chronic heart failure therapies have demonstrated success in slowing the progression of the disease and in reducing both mortality and morbidity in large-scale clinical trials. However, these successes have been limited to heart failure with reduced ejection fraction (HF-REF), showing only moderate benefits in heart failure with preserved ejection fraction (HF-PEF). Despite the lack of strong clinical evidence, guideline-recommended HF-REF therapies are widely used to treat HF-PEF.

“Based on this, drug developers have historically only targeted HF-REF in their drug strategies. With HF-PEF on the rise, however, this patient cohort represents a lucrative opportunity for pharmaceutical companies such as Novartis, which recently launched its first-in-class angiotensin receptor-neprilysin inhibitor Entresto in the U.S. for HF-REF, and is currently conducting late-stage trials of the drug in HF-PEF patients.”

GlobalData anticipates Entresto’s label expansions to HF-PEF to be approved in 2020, which will boost the drug’s uptake dramatically. Due to the lack of evidence-based therapies for HF-PEF, if Entresto proves to be efficacious in this patient, it will help Novartis further penetrate the heart failure market, undoubtedly benefitting the company immensely.

Hamson concluded: “Although it is thought that Entresto will fulfill a major unmet need over the forecast period, it is important to acknowledge that others will remain. For example, effective treatment of patients with multiple comorbidities, particularly those with renal impairment, will remain elusive. GlobalData does not expect this unmet need to be fulfilled during the forecast period, although the recent FDA [U.S. Food and Drug Administration] approval of several potassium-binding agents to treat hyperkalemia may relieve the burden of this unmet need to a slight extent.”

For more information: www.globaldata.com

Read the related article "Device Technologies to Reduce Heart Failure Readmissions."

Related Content

Novel Therapeutic Approach Effective at Reducing Pressure for Heart Failure Patients

Image courtesy of Kapur N.K., Karas R.H., Burkhoff D., et al.

News | Heart Failure | June 17, 2019
Results from a first-in-man proof of concept study found occlusion of the superior vena cava (SVC) rapidly and...
Tafamidis meglumine (Vyndaqel) is one of two new drugs cleared by the FDA for the treatment of the cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. U.S. Food and Drug Administration (FDA) approved tafamidis meglumine (Vyndaqel) and tafamidis (Vyndamax) capsules for the treatment of the cardiomyopathy.

Tafamidis meglumine (Vyndaqel) is one of two new drugs cleared by the FDA for the treatment of the cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. 

Technology | Heart Failure | May 06, 2019
May 6, 2019 — The U.S.
The Aortic intra-aortic axial flow pump is designed to unload the heart and increase renal perfusion in heart failure patients experiencing cardiorenal syndrome.

The Aortic intra-aortic axial flow pump is designed to unload the heart and increase renal perfusion in heart failure patients experiencing cardiorenal syndrome.

Feature | Heart Failure | April 29, 2019 | Will Clifton, M.D.
The heart and kidneys are inextricably linked through a diverse web of hemodynamic, neural and hormonal mechanisms.
Diabetes Drug May Reverse Heart Failure
News | Heart Failure | April 19, 2019
Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that the recently developed antidiabetic...
Diabetes Drug Effective Against Heart Failure in Wide Spectrum of Patients
News | Heart Failure | March 29, 2019
The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of patients and are...
New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsartan (Entresto) continued to deliver reductions in the heart failure biomarker N-terminal pro–B-type natriuretic peptide (NT-proBNP), an established biomarker for heart failure severity and prognosis.[1] The data was presented as a late-breaker at the American College of Cardiology (ACC) 2019 Annual Scientific Session in March.
News | Heart Failure | March 27, 2019
March 27, 2019 —New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsa
Toilet Seat Detects Congestive Heart Failure

Nicholas Conn, a postdoctoral fellow at RIT and founder and CEO of Heart Health Intelligence, is part of the university team that has developed a toilet-seat based cardiovascular monitoring system. Image courtesy of A. Sue Weisler/RIT.

News | Heart Failure | March 26, 2019
March 26, 2019 — A toilet seat-based ...
FDA Approves Optimizer Smart System for Heart Failure Patients offers cardiac contractility modulation.
Technology | Heart Failure | March 21, 2019
The U.S. Food and Drug Administration (FDA) approved Impulse Dynamics’ Optimizer Smart system for treating patients...
William T. Abraham, M.D., Joins V-Wave as Chief Medical Officer

William T. Abraham, M.D., in an interview with DAIC Editor Dave Fornell at TCT 2016.

News | Heart Failure | March 12, 2019
V-Wave Ltd. announced that renowned heart failure cardiologist William T. Abraham, M.D., is joining V-Wave as chief...
Overlay Init